Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12069014 | 0.84 | SCN9A (0.34) | USP2TSHRCA2ITGB3ITGA2B | |
| SCHEMBL1724563 | 0.84 | SCN9A (0.34) | USP2TSHRCA2ITGB3ITGA2B | |
| SCHEMBL12071190 | 0.84 | SCN9A (0.34) | USP2TSHRCA2ITGB3ITGA2B | |
| SCHEMBL24108521 | 0.82 | ITGB3 (0.39) | USP2TSHRITGB3ITGA2BMMP2 | |
| SCHEMBL10076157 | 0.82 | ITGB3 (0.39) | USP2TSHRITGB3ITGA2BMMP2 | |
| SCHEMBL12863143 | 0.82 | TGFBR1 (0.39) | CA2ITGB3ITGA2B | |
| SCHEMBL10076122 | 0.78 | CA14 (0.42) | CA2ITGB3ITGA2BCA12CA1 | |
| SCHEMBL18212160 | 0.78 | ALDH1A1 (0.44) | CA2CA1MMP1MMP2MMP8 | |
| SCHEMBL14640705 | 0.78 | ALDH1A1 (0.44) | CA2CA1MMP1MMP2MMP8 | |
| SCHEMBL15374283 | 0.78 | ALDH1A1 (0.44) | CA2CA1MMP1MMP2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140011799-A1 | SULFONYL CONTAINING BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011799-A1 | SULFONYL CONTAINING BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LPL, LIPE | USP2 801/4885TSHR 3677/4885CA2 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.